IPP Bureau
Al-Futtaim partners with TytoCare to expand digital health services
By IPP Bureau - January 24, 2022
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
Eplontersen granted Orphan Drug Designation in the US
By IPP Bureau - January 24, 2022
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Omicron is now in community transmission in India: INSACOG
By IPP Bureau - January 23, 2022
The country is sixth among the most affected countries by active cases
Pfizer and OPKO update on the Biologics License Application for Somatrogon
By IPP Bureau - January 22, 2022
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
USFDA expands use of Remdesivir for Covid-19
By IPP Bureau - January 22, 2022
Previously, the use of the drug was limited to patients requiring hospitalization
Lannett receives USFDA safety review for biosimilar insulin glargine
By IPP Bureau - January 22, 2022
Go-ahead for pivotal clinical trial which is expected to commence by March
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
By IPP Bureau - January 22, 2022
UCB plans to submit regulatory applications in Q3 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
By IPP Bureau - January 22, 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study
By IPP Bureau - January 21, 2022
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
By IPP Bureau - January 21, 2022
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Bristol Myers Squibb receives approval for Abecma in Japan
By IPP Bureau - January 21, 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
DefiniGen promotes Dr Chris Kirton to CEO
By IPP Bureau - January 21, 2022
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
By IPP Bureau - January 21, 2022
Biocon has reported consolidated financial results for the period ended December 31, 2021
Palleon announces IND clearance for first-in-class cancer immunotherapy
By IPP Bureau - January 21, 2022
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
US FDA approves Idorsia’s insomnia drug
By IPP Bureau - January 21, 2022
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
